



10 - 17-02

1653

EXPRESS MAIL NO.: EL 451 598 589 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of : Dasseux, et al.

OCT 22 2002

Serial No. : 09/865,989

Group Art Unit: 1653

Filed: May 25, 2001

Examiner: Russell

TECH CENTER 1600/2900

For: APOLIPOPROTEIN A-I
AGONISTS AND THEIR
USE TO TREAT
DYSLIPIDEMIC DISORDERS

Attorney Docket No.: 9196-019-999

Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$54.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL 46	MINUS 40	= 6	× 9	\$ 54.00	× 18	\$	
INDEP. 01	MINUS 05	= 0	× 42	\$ 0.00	× 84	\$	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			140	\$	280	\$	
			TOTAL	\$ 54.00	OR	TOTAL	\$

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 16, 2002


Rahul Pathak 42,983
(Reg No.)
for Laura A. Coruzzi (Reg. No. 30,742)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of : Dasseux, et al.

Serial No. : 09/865,989

Filed: May 25, 2001

For: APOLIPOPROTEIN AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Group Art Unit: 1653

Examiner: Russell

Attorney Docket No.: 9196-019-999

UCL 22 2002
TECH CENTER 1600/2900PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Commissioner for Patents
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. §115, please enter the following amendments prior to examination of the above-captioned application.

AMENDMENTSIN THE CLAIMS

Please amend Claims 1, 16, 17, 18, 25 and 33 as follows:

1. (Twice amended) An ApoA-I agonist compound comprising:
(i) an 18 to 22-residue D-enantiomeric peptide or peptide analogue which forms an amphipathic α -helix in the presence of lipids and which comprises formula (I):



X_1 is D-Ala (a), Gly (G), D-Asn (n), D-Gln (q) or D-Pro (p);

X_2 is a D-enantiomeric aliphatic residue;

X_3 is D-Leu (l);

X_4 is a D-enantiomeric acidic residue;

X_5 is D-Leu (l) or D-Phe (f);